Ribavirin
- Generic Name
- Ribavirin
- Brand Names
- Ibavyr, Rebetol, Virazole
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O5
- CAS Number
- 36791-04-5
- Unique Ingredient Identifier
- 49717AWG6K
- Background
Producing a broad-spectrum activity against several RNA and DNA viruses, Ribavirin is a synthetic guanosine nucleoside and antiviral agent that interferes with the synthesis of viral mRNA. It is primarily indicated for use in treating hepatitis C and viral hemorrhagic fevers. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes...
- Indication
Indicated for the treatment of chronic Hepatitis C virus (HCV) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (SVR). Typically added to improve SVR and reduce relapse rates .
...
- Associated Conditions
- Chronic Hepatitis C Virus (HCV) Infection, Severe Respiratory Syncytial Virus Infection
- Associated Therapies
- -
A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients
- Conditions
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 370
- Registration Number
- NCT04155515
- Locations
- 🇨🇳
Beijing Tsinghua Changgung Hospital, Beijing, China
Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Beijing Ditan Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT04071353
- Locations
- 🇨🇳
liver disease center, Beijing Ditan Hospital, Beijing, Beijing, China
Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Patients With Lassa Fever
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 2
- Registration Number
- NCT03889106
- Locations
- 🇸🇱
Kenema Government Hospital, Kenema, Sierra Leone
Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)
- First Posted Date
- 2019-02-07
- Last Posted Date
- 2019-02-07
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 420
- Registration Number
- NCT03833362
- Locations
- 🇷🇺
South-Ural State Medical University, Clinic of Medical Academy, Infectious Diseases Department, Chelyabinsk, Russian Federation
🇷🇺First Moscow State Medical University n.a. I.M. Sechenov, Clinic of Nephrology, Internal and Professional Diseases n.a. E.M. Tarleev, Moscow, Russian Federation
🇷🇺Moscow State Medical Stomatological University n.a. A. I. Evdokimov, Clinical Infectious Hospital #1, Clinical Infections Department, Moscow, Russian Federation
Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 24
- Registration Number
- NCT03759782
- Locations
- 🇨🇦
Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
🇨🇦Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-07-13
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 3
- Registration Number
- NCT03585725
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure
- Conditions
- Interventions
- First Posted Date
- 2018-06-08
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 40
- Registration Number
- NCT03549832
- Locations
- 🇪🇬
Assiut University Hopsital, Assiut, Egypt
DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 979
- Registration Number
- NCT03537196
- Locations
- 🇻🇳
Hai Phong University of Medicine and Pharmacy, Hai Phong, Vietnam
🇻🇳Viet Tiep Hospital, Hải Phòng, Vietnam
Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2018-03-05
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- Kawin Technology Share-holding Co., Ltd.
- Target Recruit Count
- 136
- Registration Number
- NCT03453346
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Chinese PLA 302 Hospital, Beijing, Beijing, China
🇨🇳Capital Medical University Affiliated Beijing You'an Hospital, Beijing, Beijing, China
Effect of Recombinant Human Interferon α-2b Spray on Herpangina
- Conditions
- Interventions
- First Posted Date
- 2017-08-30
- Last Posted Date
- 2019-03-07
- Lead Sponsor
- Children's Hospital of Fudan University
- Target Recruit Count
- 668
- Registration Number
- NCT03266601
- Locations
- 🇨🇳
Children's Hospital of Fudan University, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.